Microvesicles as Emerging Biomarkers and Therapeutic Targets in Cardiometabolic Diseases.
10.1016/j.gpb.2017.03.006
- Author:
Yan CHEN
1
;
Guangping LI
2
;
Ming-Lin LIU
3
,
4
,
5
Author Information
1. Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, China.
2. Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, China. Electronic address: tjcardiol@tijmu.edu.cn.
3. Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, Temple University School of Medicine, Philadelphia, PA 19140, USA
4. Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19140, USA
5. Philadelphia VA Medical Center, Philadelphia, PA 19140, USA. Electronic address: liuml@mail.med.upenn.edu.
- Publication Type:Journal Article
- Keywords:
Biomarker;
Cardiometabolic disease;
Exosome;
Microparticle;
Microvesicle
- MeSH:
Biomarkers;
metabolism;
Cardiovascular Diseases;
blood;
diagnosis;
therapy;
Cell Communication;
Cell-Derived Microparticles;
metabolism;
Humans;
Metabolic Diseases;
blood;
diagnosis;
therapy
- From:
Genomics, Proteomics & Bioinformatics
2018;16(1):50-62
- CountryChina
- Language:English
-
Abstract:
Microvesicles (MVs, also known as microparticles) are small vesicles that originate from plasma membrane of almost all eukaryotic cells during apoptosis or activation. MVs can serve as extracellular vehicles to transport bioactive molecules from their parental cells to recipient target cells, thereby serving as novel mediators for intercellular communication. Importantly, more and more evidence indicates that MVs could play important roles in early pathogenesis and subsequent progression of cardiovascular and metabolic diseases. Elevated plasma concentrations of MVs, originating from red blood cells, leukocytes, platelets, or other organs and tissues, have been reported in various cardiometabolic diseases. Circulating MVs could serve as potential biomarkers for disease diagnosis or therapeutic monitoring. In this review, we summarized recently-published studies in the field and discussed the role of MVs in the pathogenesis of cardiometabolic diseases. The emerging values of MVs that serve as biomarker for non-invasive diagnosis and prognosis, as well as their roles as novel therapeutic targets in cardiometabolic diseases, were also described.
